E

Exelixis
D

EXEL

45.600
USD
0.79
(1.76%)
مغلق
حجم التداول
167,048
الربح لكل سهم
2
العائد الربحي
-
P/E
21
حجم السوق
12,435,497,568
أصول ذات صلة
ABBV
ABBV
-0.465
(-0.24%)
190.325 USD
AZN
AZN
-1.055
(-1.43%)
72.640 USD
BMY
BMY
-0.525
(-1.07%)
48.455 USD
C
CRVS
-0.05500
(-1.16%)
4.70000 USD
INCY
INCY
-0.300
(-0.43%)
70.180 USD
MRK
MRK
0.570
(0.68%)
84.730 USD
N
NKTR
0.420
(1.71%)
25.020 USD
PFE
PFE
-0.555
(-2.19%)
24.810 USD
المزيد
الأخبار المقالات

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.